Flurandrenolide

Mechanism-of-action classes: Corticosteroid Hormone Receptor Agonists; Glucocorticoid Receptor Agonists; Lipoxygenase Inhibitors.

• Flurandrenolide Lotion USP, 0.05% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

• Topical corticosteroids are contraindicated in patients with a history of hypersensitivity to any of the components of these preparations.contraindicated

Shake well before using. A small quantity of Flurandrenolide Lotion USP, 0.05% should be rubbed gently into the affected area 2 or 3 times daily. Therapy should be discontinued when control is achieved. If no improvement is seen within 2 weeks, reassessment of the diagnosis may be necessary. Flurandrenolide Lotion USP, 0.05% should not be used with occlusive dressings unless directed by a physician. Tight-fitting diapers or plastic pants may constitute occlusive dressings.

The following local adverse reactions are reported infrequently with topical corticosteroids but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: Burning Itching Irritation Dryness Folliculitis Hypertrichosis Acneiform eruptions Hypopigmentation Perioral dermatitis Allergic contact dermatitis The following may occur more frequently with occlusive dressings: Maceration of the skin Secondary infection Skin atrophy Striae Miliaria Postmarketing Adverse Reactions The following adverse reactions have been identified during post approval use of flurandrenolide lotion. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Skin : skin striae, hypersensitivity, skin atrophy, contact dermatitis, and skin discoloration.

Usage in Pregnancy - Pregnancy Category C - Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent cortico-steroids have been shown to be teratogenic after dermal application in laboratory animals. There are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively for pregnant patients or in large amounts or for prolonged periods of time.

Metabolism

- The extent of percutaneous absorption of topical corticosteroids is determined by many factors, including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings. Topical corticosteroids can be absorbed from normal intact skin.

Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects ( see PRECAUTIONS ).

• Oct 18, 1965NDANDA012806Ina Pharms
• Jul 29, 1969NDANDA016455Almirall
• Aug 30, 2016ANDAANDA207133Padagis Israel

1. 1Drug Ineffective278.7%
2. 2Pruritus237.4%
3. 3Nausea206.4%
4. 4Fatigue185.8%
5. 5Headache185.8%
6. 6Pain185.8%
7. 7Rash185.8%
8. 8Diarrhoea165.1%
9. 9Psoriasis165.1%
10. 10Dyspnoea144.5%
11. 11Pain In Extremity144.5%
12. 12Off Label Use134.2%
13. 13Dry Skin123.9%
14. 14Depression113.5%
15. 15Psoriatic Arthropathy113.5%

Recent PubMed references pinned to Flurandrenolide as a MeSH major topic. Citations link to pubmed.ncbi.nlm.nih.gov.

• Combination of 1,064-nm Neodymium-doped Yttrium Aluminum Garnet Laser and Steroid Tape Decreases the Total Treatment Time of Hypertrophic Scars: An Analysis of 40 Cases of Cesarean-Section Scars.
  Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] · 2020 · Tsai CH, Kao HK, Akaishi S, et al.
  PMID 31702591DOI 10.1097/DSS.0000000000002235
• Fludroxycortide cream as an alternative therapy for actinic cheilitis.
  Clinical oral investigations · 2019 · de Oliveira Bezerra HI, Gonzaga AKG, da Silveira ÉJD, et al.
  PMID 30673866DOI 10.1007/s00784-019-02823-1
• In vitro penetration through the skin layers of topically applied glucocorticoids.
  Drug testing and analysis · 2018 · Carrer V, Alonso C, Oliver MA, et al.
  PMID 29788546DOI 10.1002/dta.2412
• Transmittance properties of flurandrenolide tape for psoriasis: helpful adjunct to phototherapy.
  Journal of cutaneous medicine and surgery · 2000 · Setaluri V, Clark AR, Feldman SR, et al.
  PMID 11231197DOI 10.1177/120347540000400404
• Comparative efficacy of once-daily flurandrenolide tape versus twice-daily diflorasone diacetate ointment in the treatment of psoriasis.
  Journal of the American Academy of Dermatology · 1998 · Krueger GG, O'Reilly MA, Weidner M, et al.
  PMID 9486672DOI 10.1016/s0190-9622(98)70238-5
• Discrete papular mucinosis responding to intralesional and topical steroids.
  Archives of dermatology · 1992 · Reynolds NJ, Collins CM, Burton JL, et al.
  PMID 1599285
• Isotretinoin-associated granulation tissue treated with occlusive corticosteroid tape.
  Journal of the American Academy of Dermatology · 1985 · Azulay DR, Azulay-Abulafia L
  PMID 2934440DOI 10.1016/s0190-9622(85)80451-5
• [Contact allergy to fludroxycortid and cetyl alcohol].
  Dermatosen in Beruf und Umwelt. Occupation and environment · 1985 · Hausen BM, Kulenkamp D
  PMID 3987518

The 2 most recently updated of 2 ClinicalTrials.gov registrations naming Flurandrenolide as an intervention. Registration is not evidence of efficacy or safety — reference crosswalk only.

• Steroid Impregnated Tape in the Treatment of Over-granulating Peritoneal Dialysis Exit Sites
  Completed · Phase 3 · Interventional · 32 enrolled · University Hospital Birmingham NHS Foundation Trust
  NCT01996930updated 2017-11-06
• Haelan and Nutrition in Cancer Patients
  Terminated · Phase 2 · Interventional · 6 enrolled · M.D. Anderson Cancer Center
  NCT00558558updated 2016-05-13

Frequently asked questions

How does Flurandrenolide work?

Mechanism-of-action classes: Corticosteroid Hormone Receptor Agonists; Glucocorticoid Receptor Agonists; Lipoxygenase Inhibitors.

What is Flurandrenolide used for?

According to FDA labeling, Flurandrenolide carries indications including: Flurandrenolide Lotion USP, 0.05% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.. This is a reference summary of labeled uses, not medical advice or a treatment recommendation.

What class of drug is Flurandrenolide?

Flurandrenolide is classified as Corticosteroids, potent (group III), Corticosteroid, Corticosteroid Hormone Receptor Agonists, Glucocorticoid Receptor Agonists, Lipoxygenase Inhibitors, Antipruritic Activity, Decreased Glucocorticoid Secretion, Decreased Immunologically Active Molecule Activity, Vasoconstriction.

What are the brand names for Flurandrenolide?

Flurandrenolide is marketed under brand names including Cordran.

What are the contraindications for Flurandrenolide?

Flurandrenolide labeling lists contraindications including: Topical corticosteroids are contraindicated in patients with a history of hypersensitivity to any of the components of these preparations.. Always consult the full prescribing information and a clinician.